We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.30 | 64.85 | 65.53 | 64.33 | 65.51 | 7,822,721 | 05:00:04 |
From May 2019 to May 2024
By Colin Kellaher
Shares of Forty Seven Inc. rose more than 60% in early trading Monday after the immuno-oncology company agreed to be acquired by Gilead Sciences Inc. for about $4.9 billion.
Gilead will pay $95.50 a share in cash for Forty Seven, a nearly 65% premium to Friday's closing price of $58 and a 96% increase from Thursday's closing price of $48.79--before Bloomberg reported that Gilead was circling Forty-Seven.
Forty Seven shares were recently trading at $93.74, up 61.6%.
Shares of Gilead, which gains a boost to its immuno-oncology portfolio with the addition of Forty Seven's lead candidate magrolimab, gained 2.9% to $71.40.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 02, 2020 10:37 ET (15:37 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
